Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 104
Filter
1.
Org Lett ; 22(1): 257-260, 2020 01 03.
Article in English | MEDLINE | ID: mdl-31860319
2.
Am J Med Sci ; 354(3): 310-318, 2017 09.
Article in English | MEDLINE | ID: mdl-28918839

ABSTRACT

BACKGROUND: Prostaglandin E2 (PGE2) regulates renin expression in renal juxtaglomerular cells. PGE2 acts through E-prostanoid (EP) receptors in the renal collecting duct (CD) to regulate sodium and water balance. CD cells express EP1 and EP4, which are linked to protein kinase C (PKC) and PKA downstream pathways, respectively. Previous studies showed that the presence of renin in the CD, and that of PKC and PKA pathways, activate its expression. The (pro)renin receptor (PRR) is also expressed in CD cells, and its activation enhances cyclooxygenase-2 (COX-2) through extracellular signal-regulated kinase (ERK). We hypothesized that PGE2 stimulates prorenin and renin synthesis leading to subsequent activation of PRR and upregulation of COX-2. METHODS: We used a mouse M-1 CD cell line that expresses EP1, EP3 and EP4 but not EP2. RESULTS: PGE2 (10-6M) treatment increased prorenin and renin protein levels at 4 and 8 hours. No differences were found at 12-hour after PGE2 treatment. Phospho-ERK was significantly augmented after 12 hours. COX-2 expression was decreased after 4 hours of PGE2 treatment, but increased after 12 hours. Interestingly, the full-length form of the PRR was upregulated only at 12 hours. PGE2-mediated phospho-ERK and COX-2 upregulation was suppressed by PRR silencing. CONCLUSIONS: Our results suggest that PGE2 induces biphasic regulation of COX-2 through renin-dependent PRR activation via EP1 and EP4 receptors. PRR-mediated increases in COX-2 expression may enhance PGE2 synthesis in CD cells serving as a buffer mechanism in conditions of activated renin-angiotensin system.


Subject(s)
Cyclooxygenase 2/biosynthesis , Dinoprostone/pharmacology , Kidney Tubules, Collecting/drug effects , Receptors, Cell Surface/metabolism , Renin/metabolism , Animals , Blotting, Western , Cell Culture Techniques , Cell Line , Gene Knockdown Techniques , Kidney Tubules, Collecting/cytology , Kidney Tubules, Collecting/metabolism , MAP Kinase Signaling System/drug effects , Mice , Phosphorylation , Receptors, Cell Surface/genetics , Receptors, Prostaglandin E/biosynthesis , Time Factors , Up-Regulation , Prorenin Receptor
3.
Am J Rhinol Allergy ; 29(5): 322-8, 2015.
Article in English | MEDLINE | ID: mdl-26358341

ABSTRACT

BACKGROUND: Several studies have indicated that prostaglandin E2 and E-prostanoid (EP) receptors play a role in the pathogenesis of chronic rhinosinusitis (CRS) in white populations. However, until now there was no report about EP receptor expression and its role in the pathophysiology of CRS in Chinese patients. OBJECTIVE: To investigate the expression profiles of EP receptors, including EP1, EP2, EP3, and EP4 receptors in different Chinese patients with CRS with aspirin tolerance. METHODS: Nasal biopsy specimens were obtained from 12 controls, 12 patients with CRS without nasal polyps (CRSsNP), 12 with eosinophilic CRS with nasal polyps (CRSwNP), and 16 with noneosinophilic CRSwNP. Histopathologic characteristics were observed under a light microscope. Immunostaining was used to examine tissue localization of EP receptors. Messenger RNA and protein expression of EP receptors were examined by means of quantitative RT-polymerase chain reaction and Western blot, respectively. RESULTS: Different types of CRS presented different histopathologic hallmarks. EP receptors were expressed mainly on epithelium, glands, and infiltrating inflammatory cells in nasal tissue. In controls, patients with CRSsNP, and those with noneosinophilic CRSwNP, EP4 mRNA levels were higher than EP1, EP2, and EP3 receptors. EP2 was downexpressed, and EP1 was upexpressed in patients with eosinophilic CRSwNP. When comparing EP receptor expression among different groups, Messenger RNA and protein of EP1 receptor were significantly enhanced in eosinophilic CRSwNP, but EP2, EP3, and EP4 receptors did not show significant differences. CONCLUSION: EP receptor expressions present different features in healthy subjects and patients with CRS. The upregulated EP1 receptor in eosinophilic CRSwNP might be associated with excessive infiltrations of eosinophils and other inflammatory cells. The accurate role of the four EP receptors in the pathogenesis of different CRS remains to be further explored.


Subject(s)
Aspirin/therapeutic use , Drug Tolerance/genetics , Gene Expression Regulation , RNA, Messenger/genetics , Receptors, Prostaglandin E/genetics , Rhinitis/genetics , Sinusitis/genetics , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Biopsy , Blotting, Western , China/epidemiology , Chronic Disease , Female , Humans , Immunohistochemistry , Male , Middle Aged , Nasal Mucosa/metabolism , Nasal Mucosa/pathology , Prevalence , Real-Time Polymerase Chain Reaction , Receptors, Prostaglandin E/biosynthesis , Rhinitis/drug therapy , Rhinitis/epidemiology , Sinusitis/drug therapy , Sinusitis/epidemiology , Young Adult
4.
J Urol ; 193(6): 1987-93, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25595860

ABSTRACT

PURPOSE: We evaluated PGE2 and EP receptor in patients with interstitial cystitis. MATERIALS AND METHODS: Enrolled in the study were 20 female patients with interstitial cystitis (11 with and 9 without Hunner lesions), 9 female controls with another urological disease who needed a cystoscopic procedure and 10 normal volunteers. In all participants we determined O'Leary-Sant symptom and problem scores, and obtained voluntary urine specimens for PGE2 analysis. Using anesthesia the bladder was distended by saline in stepwise fashion from 100 ml to maximum capacity in patients with interstitial cystitis. Each time the infused saline was retrieved for PGE2 analysis. We also measured PGE2 and the expression of EP receptor mRNA in bladder biopsy tissue in patients with interstitial cystitis. RESULTS: Symptom and problem indexes in patients with interstitial cystitis and Hunner lesions were significantly higher than in patients with interstitial cystitis without Hunner lesions. Urinary PGE2 in patients with interstitial cystitis and Hunner lesions was significantly higher than in patients with interstitial cystitis without lesions, controls and normal volunteers. PGE2 in retrieved saline in patients with interstitial cystitis and Hunner lesions increased depending on infusion volume but not in patients with interstitial cystitis without lesions. PGE2 content in bladder biopsy tissue was significantly higher in patients with interstitial cystitis and Hunner lesions than in controls. In patients with interstitial cystitis and Hunner lesions the expression of EP1 and EP2 mRNA was significantly higher than in controls. CONCLUSIONS: Our study showed increased PGE2 production and mRNA expression of EP1 and EP2 receptors in the bladder in patients with interstitial cystitis and Hunner lesions. Further studies are warranted to explore the pathophysiological and therapeutic implications.


Subject(s)
Cystitis, Interstitial/metabolism , Dinoprostone/analysis , Dinoprostone/biosynthesis , Receptors, Prostaglandin E/analysis , Receptors, Prostaglandin E/biosynthesis , Aged , Female , Humans , Middle Aged , Pilot Projects , Prospective Studies
5.
Spine (Phila Pa 1976) ; 39(3): 207-12, 2014 Feb 01.
Article in English | MEDLINE | ID: mdl-24253784

ABSTRACT

STUDY DESIGN: This study used immunohistochemistry and an enzyme immunoassay to quantify interleukin-1α (IL-1α) and prostaglandin E2 (PGE2) levels in the spinal cord of rats at 1 day after painful cervical facet joint injury. OBJECTIVE: The objective of this study was to determine to what extent spinal inflammation is initiated early after a painful loading-induced injury of the C6-C7 facet joint in a rat model. SUMMARY OF BACKGROUND DATA: A common source of neck pain, the cervical facet joint is susceptible to loading-induced injury, which can lead to persistent pain. IL-1α and PGE2 are associated with joint inflammation and pain, both locally in the joint and centrally in the spinal cord. Joint inflammation has been shown to contribute to pain after facet joint injury. Although spinal neuronal hyperactivity is evident within 1 day of painful facet injury, it is unknown if inflammatory mediators, such as IL-1α and PGE2, are also induced early after painful injury. METHODS: Rats underwent either a painful C6-C7 facet joint distraction or sham procedure. Mechanical sensitivity was assessed, and immunohistochemical and enzyme immunoassay techniques were used to quantify IL-1α and PGE2 expression in the spinal cord at day 1. RESULTS: Both IL-1α and PGE2 were significantly elevated (P≤ 0.04) at day 1 after painful injury. Moreover, although both spinal IL-1α and PGE2 levels were correlated with the withdrawal threshold in response to mechanical stimulation of the forepaw, this correlation was only significant (P = 0.01) for PGE2. CONCLUSION: The increased expression of 2 inflammatory markers in the spinal cord at 1 day after painful joint injury suggests that spinal inflammation may contribute to the initiation of pain after cervical facet joint injury. Further studies will help identify functional roles of both spinal IL-1α and PGE2 in loading-induced joint pain. LEVEL OF EVIDENCE: N/A.


Subject(s)
Cervical Vertebrae/injuries , Dinoprostone/biosynthesis , Interleukin-1alpha/biosynthesis , Myelitis/pathology , Pain/pathology , Zygapophyseal Joint/injuries , Animals , Cervical Vertebrae/metabolism , Dinoprostone/genetics , Gene Expression Regulation , Male , Myelitis/metabolism , Pain/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E/genetics , Spinal Cord/metabolism , Spinal Cord/pathology , Time Factors
6.
Reprod Biol Endocrinol ; 10: 3, 2012 Jan 18.
Article in English | MEDLINE | ID: mdl-22257560

ABSTRACT

BACKGROUND: Prostaglandins are important for female reproduction. Prostaglandin-E2 acts via four different receptor subtypes, EP1, EP2, EP3 and EP4 whereas prostaglandin-F2alpha acts through FP. The functions of prostaglandins depend on the expression of their receptors in different uterine cell types. Our aim was to investigate the expression of EPs and FP in rat uterus and to identify the regulation by estradiol, progesterone and estrogen receptor (ER) selective agonists. METHODS: We performed four different rat experiments involving treatments with estradiol, progesterone and ER agonists. Real-time PCR and immunohistochemistry were employed to evaluate receptor expression. RESULTS: Our results showed that all mRNAs and proteins of EPs and FP are expressed in the rat uterus. The expression pattern and intensity of immunostaining vary between different cell types and treatments. The mRNA expression of all EPs and FP are downregulated by estradiol and the ERalpha specific agonist PPT, whereas the ERbeta specific agonist DPN downregulates only EP2 and EP4. The protein expression however, showed an increase in EP2 and EP3 after estradiol treatment. When treated with estradiol and progesterone in combination, the expressions of EP1 and EP3 are upregulated. CONCLUSIONS: Regulation of EPs and FP expression by estradiol appears to be mainly modulated via ERalpha for EP1, EP3 and FP, while EP2 and EP4 also are affected by the ERbeta selective ligand. Our immunohistochemical data shows a cell specific regulation of prostaglandin receptors under the influence of ovarian steroids, where EP2 is estrogen regulated in all uterine tissues examined. EP1 and EP3 are upregulated by the combination of estradiol and progesterone. Thus, our observations indicate that estradiol and progesterone regulate the mRNA and protein expression of EPs and FP in a receptor and tissue specific way.


Subject(s)
Estradiol/pharmacology , Progesterone/pharmacology , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin/biosynthesis , Animals , Down-Regulation , Estradiol/administration & dosage , Estrogen Receptor alpha/agonists , Estrogen Receptor beta/agonists , Female , Nitriles/pharmacology , Ovariectomy , Phenols/pharmacology , Pyrazoles/pharmacology , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Prostaglandin/drug effects , Receptors, Prostaglandin/genetics , Receptors, Prostaglandin E/drug effects , Receptors, Prostaglandin E/genetics , Uterus/metabolism
7.
Anticancer Res ; 31(2): 597-605, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21378344

ABSTRACT

BACKGROUND: The clinical significance of prostaglandin E2 receptor (EPR) expression in renal cell carcinoma (RCC) tissues remains unclear. Patients and Μethods: Four subtypes of EPRs were examined in 112 human RCC tissues by immunohistochemical and Western blot analysis. The relationships between EPR immunoreactivity score (IS) and various pathological features and survival were then analyzed. RESULTS: The IS of EP4R was significantly higher (p < 0.001) in cancer cells (mean = 2.7 and SD = 2.1) than in normal kidney tissues (1.8 and 1.2). EP4R expression correlated with pT stage, metastasis, and grade. EP2R expression was also associated with metastasis. Expressions of both EP2R and EP4R were found to be significant predictors for cause-specific survival on Kaplan-Meier survival analysis (p = 0.006 and 0.023, respectively). CONCLUSION: EP2R and EP4R may play important roles in malignant behavior. EP4R in particular was closely associated with pathological features, implicating this receptor as a potential therapeutic target in patients with RCC.


Subject(s)
Carcinoma, Renal Cell/metabolism , Kidney Neoplasms/metabolism , Receptors, Prostaglandin E/biosynthesis , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Cell Membrane/metabolism , Cytoplasm/metabolism , Female , Humans , Immunohistochemistry , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Male , Middle Aged , Predictive Value of Tests , Receptors, Prostaglandin E/classification , Survival Rate
8.
J Allergy Clin Immunol ; 128(1): 66-72.e1, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21397936

ABSTRACT

BACKGROUND: Researchers have debated whether regulation of the COX enzymes (COX-1 and COX-2), which mediate production of prostaglandins (PGs), affects the pathogenesis of nasal polyps (NPs) and aspirin-intolerant asthma (AIA). OBJECTIVE: We investigated the roles of PGE(2), COX-1 and COX-2, and PGE(2) receptors in the development of NPs and AIA by measuring their expression in fibroblasts derived from nasal mucosa (NM) and NPs. METHODS: Fibroblasts were isolated from the NM of subjects without asthma who had septal deviation, turbinate hypertrophy, or both (control subjects, n = 7); NPs of aspirin-tolerant nonasthmatic patients (n = 7); and NPs of patients with asthma who were intolerant of aspirin (n = 7). Polyp samples were collected during endoscopic surgery. Cultures were stimulated with IL-1ß (10 ng/mL) for 72 hours. We used ELISA, immunoblotting, and immunofluorescence analyses to measure secretion of PGE(2), expression of COX-1 and COX-2, and expression of the PGE(2) receptors EP1 to EP4. RESULTS: Compared with NM from control subjects, PGE(2) concentrations were significantly lower in IL-1ß-stimulated fibroblasts from patients with NPs who were tolerant to aspirin and even lower in polyps from patients with AIA. Similarly, IL-1ß exposure induced the expression of COX-1 and COX-2 in fibroblasts from NM of control subjects, had only moderate effects on fibroblasts from NPs of aspirin-tolerant nonasthmatic patients, and almost no effect on fibroblasts from NPs of patients with AIA. IL-1ß also induced expression of EP2 in fibroblasts from control NM but not in fibroblasts from NPs of aspirin-tolerant nonasthmatic patients or those with AIA. CONCLUSION: Alterations in the COX pathway (ie, reduced production of PGE(2) and lack of upregulation of COX-1, COX-2, and EP2 under conditions of inflammation) are associated with NPs in patients with or without AIA.


Subject(s)
Aspirin/adverse effects , Asthma/metabolism , Dinoprostone/biosynthesis , Nasal Polyps/metabolism , Prostaglandin-Endoperoxide Synthases/biosynthesis , Adult , Asthma/chemically induced , Cells, Cultured , Dinoprostone/analysis , Enzyme-Linked Immunosorbent Assay , Female , Fibroblasts/metabolism , Fluorescent Antibody Technique , Humans , Immunoblotting , Male , Middle Aged , Nasal Mucosa/metabolism , Receptors, Prostaglandin E/biosynthesis
9.
Carcinogenesis ; 32(1): 86-92, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20974686

ABSTRACT

Melanoma is the leading cause of death from skin disease due, in large part, to its propensity to metastasize. We have examined the effect of berberine, an isoquinoline alkaloid, on human melanoma cancer cell migration and the molecular mechanisms underlying these effects using melanoma cell lines, A375 and Hs294. Using an in vitro cell migration assay, we show that over expression of cyclooxygenase (COX)-2, its metabolite prostaglandin E2 (PGE2) and PGE2 receptors promote the migration of cells. We found that treatment of A375 and Hs294 cells with berberine resulted in concentration-dependent inhibition of migration of these cells, which was associated with a reduction in the levels of COX-2, PGE2 and PGE2 receptors (EP2 and EP4). Treatment of cells with celecoxib, a COX-2 inhibitor, or transient transfection of cells with COX-2 small interfering RNA, also inhibited cell migration. Treatment of the cells with 12-O-tetradecanoylphorbol-13-acetate (TPA), an inducer of COX-2 or PGE2, enhanced cell migration, whereas berberine inhibited TPA- or PGE2-promoted cell migration. Berberine reduced the basal levels as well as PGE2-stimulated expression levels of EP2 and EP4. Treatment of the cells with the EP4 agonist stimulated cell migration and berberine blocked EP4 agonist-induced cell migration activity. Moreover, berberine inhibited the activation of nuclear factor-kappa B (NF-κB), an upstream regulator of COX-2, in A375 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-κB, inhibited cell migration. Together, these results indicate for the first time that berberine inhibits melanoma cell migration, an essential step in invasion and metastasis, by inhibition of COX-2, PGE2 and PGE2 receptors.


Subject(s)
Antineoplastic Agents/pharmacology , Berberine/pharmacology , Cell Movement/drug effects , Melanoma/metabolism , Blotting, Western , Cell Line, Tumor , Cyclooxygenase 2/biosynthesis , Cyclooxygenase 2/drug effects , Dinoprostone/biosynthesis , Gene Expression/drug effects , Humans , Melanoma/genetics , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E/drug effects , Transfection
10.
Biochem Biophys Res Commun ; 398(3): 450-6, 2010 Jul 30.
Article in English | MEDLINE | ID: mdl-20599704

ABSTRACT

Prostaglandin E(2) (PGE(2)) is a key lipid-derived compound which mediates important physiological functions in the nervous system via activation of four EP receptors (EP1-4). Recent studies have shown that altered PGE(2) signalling due to abnormal lipid peroxidation and oxidative stress may underlie some pathologies of the nervous system. The prenatal exposure to the drug misoprostol, a prostaglandin type E analogue, has also been linked to a number of neurodevelopmental defects. In the present study, we use ratiometric calcium imaging with fura-2AM as a calcium indicator to determine the effects of PGE(2) and misoprostol on calcium homeostasis in growth cones of mouse neuroblastoma (Neuro-2a) cells. Our results show that both drugs increase the amplitude of calcium transients in growth cones of Neuro-2a cells and induce neurite retraction. Moreover, quantitative real-time PCR also revealed that the mRNA expression level of the four EP receptors was significantly higher during the neurogenesis period in mouse indicating the importance of PGE(2) signalling in the nervous system.


Subject(s)
Calcium/metabolism , Dinoprostone/pharmacology , Growth Cones/drug effects , Misoprostol/pharmacology , Neurites/drug effects , Neurogenesis/drug effects , Animals , Brain/drug effects , Brain/metabolism , Cell Line, Tumor , Fluorescent Dyes/metabolism , Fura-2/analogs & derivatives , Fura-2/metabolism , Growth Cones/metabolism , Mice , Neurites/metabolism , Neurites/physiology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E/genetics
11.
J Reprod Immunol ; 85(2): 149-60, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20452033

ABSTRACT

Gene expression profiling can be of benefit in identifying critical factors in the process of disease initiation and development. However, in endometriosis it has proven difficult to identify common genes between DNA microarray studies, presumably because of tissue homogeneity in lesions and diversity in the patients' conditions. We attempted DNA microarray analysis in a mouse model for endometriosis with stable lesions and a homogeneous genetic background. Data extracted from the mouse model was then evaluated in human tissues. Mice of the ddY strain underwent surgery to remove the left side of the uterine horn, and the uterine tissue was then minced into small segments and auto-transplanted onto the left peritoneum. After 8 weeks, most of the uterine grafts were enlarged and had regenerated lumens. Comparison of the intensity of mRNA expression between grafts and normal uteri showed that genes encoding immune regulators (e.g. CXCL10) and metabolic factors (e.g. calbindin D-28K) were highly up-regulated in the grafts. Strongly inhibited genes in the grafts included prostaglandin-related factors [e.g. prostaglandin E receptor 3 (subtype EP3) and prostaglandin I2 synthase]. Variation in some candidate factors detected in the mouse model was observed by immunohistochemical studies in human adenomyosis tissues. The gene list in the present study is available for re-evaluation of past studies and provides new candidate factors potentially involved in the pathogenesis of endometriosis.


Subject(s)
Endometriosis/genetics , Endometriosis/immunology , Uterus/metabolism , Animals , Calbindins , Chemokine CXCL10/biosynthesis , Chemokine CXCL10/genetics , Disease Models, Animal , Down-Regulation , Endometriosis/metabolism , Endometriosis/pathology , Female , Gene Expression Profiling , Genetic Association Studies , Humans , Immunohistochemistry , Mice , Mice, Inbred Strains , Oligonucleotide Array Sequence Analysis , Prostaglandin-Endoperoxide Synthases/biosynthesis , Prostaglandin-Endoperoxide Synthases/genetics , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E/genetics , Receptors, Prostaglandin E, EP3 Subtype , S100 Calcium Binding Protein G/biosynthesis , S100 Calcium Binding Protein G/genetics , Up-Regulation , Uterus/immunology , Uterus/pathology , Uterus/surgery
12.
Cancer Res ; 70(9): 3697-708, 2010 May 01.
Article in English | MEDLINE | ID: mdl-20388794

ABSTRACT

Kaposi's sarcoma-associated herpes virus (KSHV) is implicated in the pathogenesis of KS, a chronic inflammation-associated malignancy. Cyclooxygenase-2 (COX-2) and its metabolite prostaglandin E2 (PGE2), two pivotal proinflammatory/oncogeneic molecules, are proposed to play roles in the expression of major KSHV latency-associated nuclear antigen-1 (LANA-1). Microsomal PGE2 synthase, PGE2, and its receptors (EP1, EP2, EP3, and EP4) were detected in KS lesions with the distinct staining of EP2/EP4 in KS lesions. In latently infected endothelial TIVE-LTC cells, EP receptor antagonists downregulated LANA-1 expression as well as Ca(2+), p-Src, p-PI3K, p-PKCzeta/lambda, and p-NF-kappaB, which are also some of the signal molecules proposed to be important in KS pathogenesis. Exogenous PGE2 and EP receptor agonists induced the LANA-1 promoter in 293 cells, and YY1, Sp1, Oct-1, Oct-6, C/EBP, and c-Jun transcription factors seem to be involved in this induction. PGE2/EP receptor-induced LANA-1 promoter activity was downregulated significantly by the inhibition of Ca(2+), p-Src, p-PI3K, p-PKCzeta/lambda, and p-NF-kappaB. These findings implicate the inflammatory PGE2/EP receptors and the associated signal molecules in herpes virus latency and uncover a novel paradigm that shows the evolution of KSHV genome plasticity to use inflammatory response for its survival advantage of maintaining latent gene expression. These data also suggest that potential use of anti-COX-2 and anti-EP receptor therapy may not only ameliorate the chronic inflammation associated with KS but could also lead to elimination of the KSHV latent infection and the associated KS lesions.


Subject(s)
Dinoprostone/metabolism , Herpesvirus 8, Human/physiology , Receptors, Prostaglandin E/metabolism , Antigens, Viral/biosynthesis , Antigens, Viral/genetics , Calcium/metabolism , Cyclooxygenase 2/biosynthesis , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Dinoprostone/biosynthesis , Dinoprostone/genetics , Down-Regulation , Endothelial Cells/virology , Gene Expression , Herpesvirus 8, Human/genetics , Herpesvirus 8, Human/metabolism , Humans , NF-kappa B/metabolism , Nuclear Proteins/biosynthesis , Nuclear Proteins/genetics , Phosphatidylinositol 3-Kinases/metabolism , Promoter Regions, Genetic , Protein Kinase C/metabolism , Receptors, Prostaglandin E/antagonists & inhibitors , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E/genetics , Sarcoma, Kaposi/metabolism , Sarcoma, Kaposi/pathology , Sarcoma, Kaposi/virology , Signal Transduction , Up-Regulation , Virus Latency , src-Family Kinases/metabolism
13.
Cancer Epidemiol Biomarkers Prev ; 19(3): 822-31, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20200425

ABSTRACT

BACKGROUND: Prostaglandin-endoperoxide synthase 2 (PTGS2, the HUGO Gene Nomenclature Committee-approved official symbol for cycloxygenase-2, COX-2) and its enzymatic product prostaglandin E2 have critical roles in inflammation and carcinogenesis through the G protein-coupled receptor PTGER2 (EP2). The PTGS2 (COX-2) pathway is a promising target for cancer therapy and chemoprevention. PTGS2 (COX-2) expression in colon cancer has been inversely associated with survival as well as tumoral microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP). However, the prognostic significance of PTGER2 expression or its relationship with MSI, CIMP, LINE-1 hypomethylation, or PTGS2 (COX-2) remains uncertain. METHODS: Using the database of 516 colorectal cancers in two prospective cohort studies with clinical outcome data, we detected PTGER2 overexpression in 169 (33%) tumors by immunohistochemistry. We analyzed MSI using 10 microsatellite markers; CIMP by MethyLight (real-time methylation-specific PCR) on an eight-marker panel [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1]; BRAF, KRAS, PIK3CA, and methylation in LINE-1 by Pyrosequencing; and CTNNB1 (beta-catenin) and TP53 (p53) by immunohistochemistry. RESULTS: PTGER2 overexpression was positively associated with the mucinous component (P = 0.0016), signet ring cells (P = 0.0024), CIMP-high (P = 0.0023), and MSI-high (P < 0.0001). In multivariate analysis, the significant relationship between PTGER2 and MSI-high persisted (adjusted odds ratio, 2.82; 95% confidence interval, 1.69-4.72; P < 0.0001). PTGER2 was not significantly associated with PTGS2 (COX-2), TP53, or CTNNB1 expression, patient survival, or prognosis. CONCLUSION: PTGER2 overexpression is associated with MSI-high in colorectal cancer. IMPACT: Our data imply potential roles of inflammatory reaction by PTGER2 upregulation in carcinogenic process to MSI-high colorectal cancer.


Subject(s)
Colorectal Neoplasms/genetics , CpG Islands/genetics , DNA Methylation/genetics , Microsatellite Instability , Receptors, Prostaglandin E/biosynthesis , Biomarkers, Tumor/genetics , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/mortality , Cyclooxygenase 2/biosynthesis , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Male , Phenotype , Prognosis , Receptors, Prostaglandin E/genetics , Receptors, Prostaglandin E, EP2 Subtype , Reverse Transcriptase Polymerase Chain Reaction , Tumor Suppressor Protein p53/biosynthesis , beta Catenin/biosynthesis
14.
Clin Exp Pharmacol Physiol ; 37(5-6): 574-80, 2010 May.
Article in English | MEDLINE | ID: mdl-20082631

ABSTRACT

1. Patent ductus arteriosus (PDA) is a common congenital heart defect in premature infants. The present study was designed to determine the role of the prostaglandin (PG) E(2) pathway in the process of ductus arteriosus (DA) maturation and functional closure. 2. Changes in PGE(2) pathway-related enzymes and receptors in DA in preterm and term rabbits were examined at both the mRNA and protein levels. In addition, responses of DA rings to Po(2) and PGE(2) were determined. 3. Circulating PGE(2) levels remained high until 2 h after birth. High levels of the EP(4) receptor were found in preterm DA. These tissues were sensitive to PGE(2), which caused vessel dilation, but were insensitive to increased Po(2). In contrast, DA tissues from term rabbits exhibited an immediate contractile response to increased Po(2) and PGE(2) treatment resulted in vasoconstriction, which was associated with increased EP(3) and decreased EP(4) receptor expression in term DA. 4. In conclusion, the preterm PDA is maintained by high levels of PGE(2), which mainly binds to the EP(4) receptor under conditions of hypoxia. In contrast, in the term DA, in which levels of the EP(3) receptor are higher than in preterm DA, exposure to PGE(2) resulted in vasoconstriction under normoxic conditions. These findings suggest that blocking the EP(4) receptor may represent a more selective treatment for the preterm PDA, whereas activating the EP(3) receptor may be more suitable for the treatment of the term PDA.


Subject(s)
Dinoprostone/physiology , Ductus Arteriosus/growth & development , Receptors, Prostaglandin E/physiology , Animals , Animals, Newborn , Dinoprostone/blood , Dinoprostone/pharmacology , Ductus Arteriosus/drug effects , Ductus Arteriosus/enzymology , Ductus Arteriosus/metabolism , Ductus Arteriosus/pathology , Ductus Arteriosus/physiopathology , Ductus Arteriosus, Patent/blood , Ductus Arteriosus, Patent/enzymology , Ductus Arteriosus, Patent/etiology , Ductus Arteriosus, Patent/pathology , Enzyme-Linked Immunosorbent Assay , Female , Gene Expression/drug effects , Gestational Age , Immunohistochemistry , In Vitro Techniques , Oxygen/pharmacology , Plasmids , Pregnancy , Premature Birth/blood , Premature Birth/enzymology , Premature Birth/metabolism , Premature Birth/pathology , RNA/biosynthesis , RNA/genetics , Rabbits , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E/genetics , Reverse Transcriptase Polymerase Chain Reaction , Vasoconstriction/drug effects
15.
FASEB J ; 24(4): 1105-16, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19897661

ABSTRACT

The molecular mechanisms that enable cyclooxygenase-2 (COX-2) and its mediator prostaglandin E2 (PGE2) to inhibit transforming growth factor-beta (TGF-beta) signaling during mammary tumorigenesis remain unknown. We show here that TGF-beta selectively stimulated the expression of the PGE2 receptor EP2, which increased normal and malignant mammary epithelial cell (MEC) invasion, anchorage-independent growth, and resistance to TGF-beta-induced cytostasis. Mechanistically, elevated EP2 expression in normal MECs inhibited the coupling of TGF-beta to Smad2/3 activation and plasminogen activator inhibitor-1 (PAI1) expression, while EP2 deficiency in these same MECs augmented Smad2/3 activation and PAI expression stimulated by TGF-beta. Along these lines, engineering malignant MECs to lack EP2 expression prevented their growth in soft agar, restored their cytostatic response to TGF-beta, decreased their invasiveness in response to TGF-beta, and potentiated their activation of Smad2/3 and expression of PAI stimulated by TGF-beta. More important, we show that COX-2 or EP2 deficiency both significantly decreased the growth, angiogenesis, and pulmonary metastasis of mammary tumors produced in mice. Collectively, this investigation establishes EP2 as a potent mediator of the anti-TGF-beta activities elicited by COX-2/PGE2 in normal and malignant MECs. Our findings also suggest that pharmacological targeting of EP2 receptors may provide new inroads to antagonize the oncogenic activities of TGF-beta during mammary tumorigenesis.-Tian, M., Schiemann, W. P. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.


Subject(s)
Cell Transformation, Neoplastic/metabolism , Cyclooxygenase 2/metabolism , Mammary Neoplasms, Animal/metabolism , Neoplasm Proteins/metabolism , Receptors, Prostaglandin E/biosynthesis , Signal Transduction , Transforming Growth Factor beta/metabolism , Animals , Cell Line, Tumor , Cell Transformation, Neoplastic/pathology , Female , Gene Expression Regulation, Neoplastic , Mammary Neoplasms, Animal/pathology , Mice , Mice, Inbred BALB C , Neoplasm Invasiveness , Plasminogen Activator Inhibitor 1/biosynthesis , Receptors, Prostaglandin E/antagonists & inhibitors , Receptors, Prostaglandin E, EP2 Subtype , Smad2 Protein/metabolism , Smad3 Protein/metabolism
16.
Eur J Cancer ; 45(17): 3087-97, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19818596

ABSTRACT

BACKGROUND: Cyclooxygenase (COX)-2 is frequently overexpressed in non-small cell lung cancer (NSCLC) and results in increased levels of prostaglandin E2 (PGE(2)), an important signalling molecule implicated in tumourigenesis. PGE(2) exerts its effects through the E prostanoid (EP) receptors (EPs1-4). METHODS: The expression and epigenetic regulation of the EPs were evaluated in a series of resected fresh frozen NSCLC tumours and cell lines. RESULTS: EP expression was dysregulated in NSCLC being up and downregulated compared to matched control samples. For EPs1, 3 and 4 no discernible pattern emerged. EP2 mRNA however was frequently downregulated, with low levels being observed in 13/20 samples as compared to upregulation in 5/20 samples examined. In NSCLC cell lines DNA CpG methylation was found to be important for the regulation of EP3 expression, the demethylating agent decitabine upregulating expression. Histone acetylation was also found to be a critical regulator of EP expression, with the histone deacteylase inhibitors trichostatin A, phenylbutyrate and suberoylanilide hydroxamic acid inducing increased expression of EPs2-4. Direct chromatin remodelling was demonstrated at the promoters for EPs2-4. CONCLUSIONS: These results indicate that EP expression is variably altered from tumour to tumour in NSCLC. EP2 expression appears to be predominantly downregulated and may have an important role in the pathogenesis of the disease. Epigenetic regulation of the EPs may be central to the precise role COX-2 may play in the evolution of individual tumours.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Epigenesis, Genetic/genetics , Gene Expression Regulation, Neoplastic/genetics , Lung Neoplasms/genetics , Receptors, Prostaglandin E/genetics , Acetylation , Antineoplastic Agents/pharmacology , Azacitidine/analogs & derivatives , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cell Proliferation/drug effects , Chromatin Assembly and Disassembly/genetics , CpG Islands/genetics , DNA Methylation , Decitabine , Gene Expression Regulation, Neoplastic/drug effects , Histone Deacetylase Inhibitors/pharmacology , Histones/metabolism , Humans , Hydroxamic Acids/pharmacology , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Phenylbutyrates/pharmacology , RNA, Messenger/genetics , Receptors, Prostaglandin E/biosynthesis , Tumor Cells, Cultured , Vorinostat
17.
J Pharmacol Exp Ther ; 331(3): 860-70, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19726696

ABSTRACT

Abscess formation is a classic host response to infection by many pathogenic microorganisms. Here, we studied the role of prostaglandins (PGs) and their signal transduction in abscess formation. Zymosan was injected into the pleural cavity of rats. Expression of enzymes involved in PG synthesis, their receptors, and cytokines in exudate leukocytes and abscesses were analyzed by polymerase chain reaction, Western blotting, and immunohistochemistry. Treatment with ketorolac, a cyclooxygenase (COX)-1 inhibitor, or N-[2-cyclohexyloxy-4-nitrophenyl] methanesulfonamide (NS-398), a COX-2 inhibitor, reduced the size of abscesses and the number of cells recovered from the abscess. COX-2 was detected in leukocytes of the exudate and a marginal area of abscesses. Among detected terminal PG synthases, the major one was cytosolic PGE synthase. Membrane-bound PGE synthase (mPGES)-1 was detected in cells that were similar to the COX-2-expressing cells in morphology and localization. A high level of the E-prostanoid (EP)(2) receptor and a low level of the EP(4) receptor were detected. The expression pattern of the EP(2) receptor paralleled that of COX-2 and mPGES-1. 11,15-O-Dimethyl PGE(2) (ONO-AE1-259), an EP(2) receptor agonist, and rolipram, a phosphodiesterase type-4 inhibitor, reversed the effects of COX inhibitors on abscess formation. In contrast, 16-(3-methoxymethyl) phenyl-omega-tetranor-3,7-dithia PGE(1) (ONO-AE1-329), an EP(4) receptor agonist, did not reverse the effects of NS-398. Moreover, NS-398 reduced the mRNA levels in exudate leukocytes of some proinflammatory and fibrogenic cytokines, which was reversed by ONO-AE1-259. These results suggest that PGE(2) generated via COX-1 and COX-2 may interact with the EP(2) receptor and may up-regulate in cAMP-dependent fashion the production of cytokines that promote abscess formation.


Subject(s)
Abscess/etiology , Dinoprostone/biosynthesis , Pleurisy/complications , Receptors, Prostaglandin E/biosynthesis , Signal Transduction , Abscess/enzymology , Abscess/metabolism , Abscess/prevention & control , Animals , Blotting, Western , Cyclooxygenase 2/biosynthesis , Cyclooxygenase 2 Inhibitors/pharmacology , Cyclooxygenase 2 Inhibitors/therapeutic use , Immunohistochemistry , Male , Pleurisy/chemically induced , Pleurisy/enzymology , Pleurisy/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Prostaglandin E/agonists , Receptors, Prostaglandin E, EP2 Subtype , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Zymosan
18.
Br J Pharmacol ; 158(3): 830-47, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19702786

ABSTRACT

BACKGROUND AND PURPOSE: In previous studies investigating cross-talk of signalling between prostaglandin (PG)E(2) receptor (EP) and the TPalpha and TPbeta isoforms of the human thromboxane (TX)A(2) receptor (TP), 17-phenyl trinor PGE(2)-induced desensitization of TP receptor signalling through activation of the AH6809 and SC19220-sensitive EP(1) subtype of the EP receptor family, in a cell-specific manner. Here, we sought to further investigate that cross-talk in human erythroleukaemic (HEL) 92.1.7 cells. EXPERIMENTAL APPROACH: Specificity of 17-phenyl trinor PGE(2) signalling and its possible cross-talk with signalling by TPalpha/TPbeta receptors endogenously expressed in HEL cells was examined through assessment of agonist-induced inositol 1,4,5-trisphosphate (IP)(3) generation and intracellular calcium ([Ca(2+)](i)) mobilization. KEY RESULTS: While 17-Phenyl trinor PGE(2) led to activation of phospholipase (PL)Cbeta to yield increases in IP(3) generation and [Ca(2+)](i), it did not desensitize but rather augmented that signalling in response to subsequent stimulation with the TXA(2) mimetic U46619. Furthermore, the augmentation was reciprocal. Signalling by 17-phenyl trinor PGE(2) was found to occur through AH6809- and SC19920-insensitive, Pertussis toxin-sensitive, G(i)/G(betagamma)-dependent activation of PLCbeta. Further pharmacological investigation using selective EP receptor subtype agonists and antagonists confirmed that 17-phenyl trinor PGE(2)-mediated signalling and reciprocal cross-talk with the TP receptors occurred through the EP(3), rather than the EP(1), EP(2) or EP(4) receptor subtype in HEL cells. CONCLUSIONS AND IMPLICATIONS: The EP(1) and EP(3) subtypes of the EP receptor family mediated intermolecular cross-talk to differentially regulate TP receptor-mediated signalling whereby activation of EP(1) receptors impaired or desensitized, while that of EP(3) receptors augmented signalling through TPalpha/TPbeta receptors, in a cell type-specific manner.


Subject(s)
Receptors, Prostaglandin E/physiology , Receptors, Thromboxane A2, Prostaglandin H2/physiology , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Calcium/metabolism , Cell Line , Cell Line, Tumor , Dinoprostone/analogs & derivatives , Dinoprostone/pharmacology , Enzyme Activation , GTP-Binding Protein alpha Subunits/physiology , Humans , Inositol 1,4,5-Trisphosphate/biosynthesis , Phospholipase C beta/metabolism , Protein Isoforms/biosynthesis , Receptor Cross-Talk , Receptors, Prostaglandin E/agonists , Receptors, Prostaglandin E/antagonists & inhibitors , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E, EP1 Subtype , Receptors, Prostaglandin E, EP3 Subtype , Signal Transduction
19.
Article in English | MEDLINE | ID: mdl-19625175

ABSTRACT

We have previously demonstrated that the EP1 subtype of PGE2 receptor is expressed in the differentiated compartment of normal human epidermis and is coupled to intracellular calcium mobilization. We therefore hypothesized that the EP1 receptor is coupled to keratinocyte differentiation. In in vitro studies, radioligand binding, RT-PCR, immunoblot and receptor agonist-induced second messenger studies demonstrate that the EP1 receptor is up-regulated by high cell density in human keratinocytes and this up-regulation precedes corneocyte formation. Moreover, two different EP1 receptor antagonists, SC51322 and AH6809, both inhibited corneocyte formation. SC51322 also inhibited the induction of differentiation-specific proteins, cytokeratin K10 and epidermal transglutaminase. We next examined the immunolocalization of the EP1 receptor in non-melanoma skin cancer in humans. Well-differentiated SCCs exhibited significantly greater membrane staining, while spindle cell carcinomas and BCCs had significantly decreased membrane staining compared with normal epidermis. This data supports a role for the EP1 receptor in regulating keratinocyte differentiation.


Subject(s)
Cell Differentiation , Keratinocytes/cytology , Keratinocytes/metabolism , Receptors, Prostaglandin E/classification , Receptors, Prostaglandin E/metabolism , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Animals , Calcium/metabolism , Humans , Immunohistochemistry , Mice , Mice, Inbred C57BL , Mice, Knockout , Phenotype , Receptors, Prostaglandin E/antagonists & inhibitors , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E, EP1 Subtype , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Tumor Cells, Cultured , Xanthones/pharmacology
20.
Article in English | MEDLINE | ID: mdl-19497718

ABSTRACT

Cyclooxygenase-1 (COX-1) behaves as a delayed response gene in rat pheochromocytoma (PC12) cells exposed to nerve growth factor (NGF). To investigate the possible targets for COX-1 generated prostanoids in the early stages of neuronal differentiation, we have examined the expression of prostanoid receptors by PC12 cells using functional assays. Prostanoid receptor-specific agonists failed to activate adenylyl cyclase in undifferentiated and NGF-treated PC12 cells; neither did they stimulate phospholipase C activity. EP3 receptor agonists and PGF(2alpha) were the only active ligands, able to inhibit forskolin-stimulated adenylyl cyclase activity. PC12 cells expressed EP3 and FP receptor mRNA, but only the responses to EP3 receptor agonists were inhibited by the EP3 receptor antagonist ONO-AE3-240. The functional role of NGF-stimulated COX-1 remains to be determined since we found no strong evidence of a role for EP3 receptors in the morphological changes induced by NGF during the early stages of differentiation of PC12 cells.


Subject(s)
Cyclooxygenase 1/metabolism , Receptors, Prostaglandin/physiology , Animals , Cell Differentiation/physiology , Dinoprostone/pharmacology , GTP-Binding Protein alpha Subunits, Gi-Go/biosynthesis , Nerve Growth Factor/pharmacology , PC12 Cells , Rats , Receptors, Prostaglandin/agonists , Receptors, Prostaglandin E/antagonists & inhibitors , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E, EP3 Subtype
SELECTION OF CITATIONS
SEARCH DETAIL
...